Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

BACKGROUND: In the BRIM-3 trial, vemurafenib was associated with risk reduction versus dacarbazine of both death and progression in patients with advanced BRAF(V600) mutation-positive melanoma. We present an extended follow-up analysis of the total population and in the BRAF(V600E) and BRAF(V600K) m...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Lancet Oncol
Главные авторы: McArthur, Grant A, Chapman, Paul B, Robert, Caroline, Larkin, James, Haanen, John B, Dummer, Reinhard, Ribas, Antoni, Hogg, David, Hamid, Omid, Ascierto, Paolo A, Garbe, Claus, Testori, Alessandro, Maio, Michele, Lorigan, Paul, Lebbé, Celeste, Jouary, Thomas, Schadendorf, Dirk, O’Day, Stephen J, Kirkwood, John M., Eggermont, Alexander M, Dréno, Brigitte, Sosman, Jeffrey A, Flaherty, Keith T, Yin, Ming, Caro, Ivor, Cheng, Suzanne, Trunzer, Kerstin, Hauschild, Axel
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4382632/
https://ncbi.nlm.nih.gov/pubmed/24508103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70012-9
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы